Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Formerly PRS-342)
Portfolio Pulse from Benzinga Newsdesk
Pieris Pharmaceuticals has received an undisclosed milestone payment from Boston Pharmaceuticals following the dosing of the first patient in a Boston Pharmaceutical-sponsored Phase 1/2 study of BOS-342 (formerly PRS-342).
August 17, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pieris Pharmaceuticals has achieved a milestone in its partnership with Boston Pharmaceuticals, which has resulted in an undisclosed payment. This could potentially boost the company's revenues.
The undisclosed payment received by Pieris Pharmaceuticals from Boston Pharmaceuticals is a positive development for the company. It not only signifies progress in their partnership but also provides a potential boost to Pieris' revenues. This could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100